-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 11, local time, the U.
According to the FDA press release, Bebtelovimab remained active against the Omicron variant
Bebtelovimab is a neutralizing IgG1 monoclonal antibody (mAb) against the SARS COV-2 spike protein, maintaining binding and neutralizing activity against all currently known and reported variants, including Omicron and BA.
The placebo-controlled portion of the trial enrolled 380 low-risk patients
Another part of the trial involved high-risk individuals
The results showed that among high-risk patients, those receiving bebtelovimab alone or in combination with other monoclonal antibodies had generally lower rates of COVID-19-related hospitalization and mortality by day 29 than previously reported in other monoclonal antibody trials
It is worth mentioning that on February 10, Eli Lilly and the US government signed an order for 600,000 doses of bebtelovimab, with a total amount of US$720 million (US$1,200/dose)
